NICE's draft guidance rejects Lilly's Alimta in NSCLC expanded maintenance indication
This article was originally published in Scrip
Executive Summary
Eli Lilly's Alimta (pemetrexed) has not been recommended for use on the UK's National Health Service (NHS) as a maintenance treatment for non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin in preliminary guidance issued by NICE, the health technology appraisal institute in England and Wales.